REFERENCES


Ramón Vilallonga*, Diego Yesteb, Albert Lecuéc, Manel Armengolb, José Manuel Forta

*aUnidad de Cirugía Endocrina, Bariátrica y Metabólica, Servicio de Cirugía General, Hospital Universitario Vall d’Hebron, European Center of Excellence (EAC-BS), Barcelona, Spain
bUnidad de Endocrinología Pediatría, Servicio de Pediatría, Hospital Universitario Vall d’Hebron, Barcelona, Spain
cUnidad de Obesidad Mórbida, Servicio de Endocrinología, Hospital Universitario Vall d’Hebron, Barcelona, Spain

d*Corresponding author.
E-mail address: vilallongapuy@hotmail.com (R. Vilallonga).

2173-5077/$ – see front matter © 2012 AEC. Published by Elsevier España, S.L. All rights reserved.

Hepatic Metastasis Marking Before Neoadjuvant Chemotherapy for Their Subsequent Location and Resection Using Non-anatomical Hepatectomy

Marque de metástasis hepática antes de quimioterapia neoadyuvante para su posterior localización y resección mediante heptectomía no anatómica

The high level of therapeutic response obtained with combinations of fluorouracil and leucovorin with oxaliplatin or irinotecan and with monoclonal antibodies such as cetuximab or bevacizumab, and the results of the EORTC trial with peri-operative chemotherapy, have encouraged us to use neoadjuvant chemotherapy in a large number of patients with liver metastases from colorectal cancer. Metastases can disappear or reduce with neoadjuvant treatment after a few cycles, in such a way that their subsequent location can become very difficult. This is aggravated when liver toxicity occurs from therapeutic agents, giving the hepatic parenchyma an echogenicity which is highly homogenous with metastases. Furthermore, as we find a real pathological complete response in only 10% of lesions that disappear, resection of the hepatic parenchyma where the metastasis was located remains necessary. In order to avoid these location problems, some authors have described a technique of marking liver metastases prior to starting neoadjuvant

Please cite this article as: Alonso Casado O, González-Moreno S, Encinas García S, Rojo Sebastián A, Olavarria Delgado A. Marque de metástasis hepática antes de quimioterapia neoadyuvante para su posterior localización y resección mediante heptectomía no anatómica. Cir Esp. 2013;91:687–689.
treatment. This involves placing one or two coils next to the metastasis under radiological control, by ultrasound or CT scan, before starting chemotherapy treatment. Once the neoadjuvant treatment has been completed, the coils can be located by intraoperative ultrasound during the surgical procedure, even though the metastasis has either disappeared, or is not visible.

The following is a case where this marking technique was necessary. The patient was a 47-year-old male diagnosed with an adenocarcinoma of the colon, 15 cm from the anal margin; the extension study of the carcinoma revealed hepatic metastasis of 2.5 cm located deep in the intersection of segments V-VI-VII-VIII (Fig. 1), but at sufficient distance from the vascular pedicles of these segments to allow a non-anatomical

Fig. 1 – The CT scan shows a 2.5 cm metastasis at the confluence of segments V-VI-VII-VIII, which is resectable by non-anatomical hepatectomy. Marking with coils prior to neoadjuvant treatment (2) allows subsequent location of the metastasis with ultrasound although it is not ultrasonically visible (3). (4) The post chemotherapy MRI scan shows the metastasis which is 1 cm in size.

Fig. 2 – Resection sample section showing a coil next to the metastasis. Resection bed in right hepatic lobule.
Electrocautery was placed mesenteric margins, the PET/CT paraaortic resection was complete, and no nodes were seen in the above of the metastasis. The MRI of the liver metastasis showed a reduction in size to 1 cm. We performed a pre-operative ultrasound which enabled us to see the metastasis. Based on these findings, the team decided to perform a one-stage hepatic resection, using intra-operative ultrasound, without being possible to clearly distinguish the metastasis. The primary tumour and preaortic lymph node metastases were resected first. We then proceeded to resect the metastasis by non-anatomical hepatectomy on segments V–VI–VII–VIII. Continuously guided by ultrasound, we resected the hepatic parenchyma area around the coils, taking into account the initial size of the lesion, and achieving at least a margin of 1 cm in depth from the coils. We performed the resection with electrocautery and ultrasonic aspirator, without hilar clamping. When the resection sample had been extracted, we confirmed the presence of an eight mm lesion with free margins, situated 8 mm from the deep margin (Fig. 2). The histology study confirmed that it was a colorectal adenocarcinoma metastasis. There were no complications in the post-operative period; the patient was discharged on the eighth day after surgery.

High risk patients with synchronous hepatic metastasis, “potentially resectable” metastasis or synchronous extrahepatic disease will be treated with chemotherapy prior to hepatic resection.5 This marking technique is indicated when these patients present with a small, deep metastasis, which is likely to disappear if there is a good response to treatment. The technique is simple, reproducible and has a low risk of complications. It allows a parenchyma-sparing resection, avoiding unnecessary major anatomical hepatectomies and having to wait for the metastasis to reappear to treat it at a second stage. In our case, only a right-sided hepatectomy could have ensured resection if the lesion had not been marked. It is important for the coil to be placed in the deep edge of the lesion, without crossing it, to prevent it from spreading. Pre-operative ultrasound, although not essential, allows us to check that the coils are easily visible. The use of intra-operative ultrasound is essential. Hepatic resection will be guided exclusively by ultrasonic image, and the resection margins will depend on the correct knowledge of this technique. Intra-operatively, it must be checked that the metastasis and/or the coils are in the resection sample.

REFERENCES


Oscar Alonso Casadoa,b, Santiago González Morenoa, Sara Encinas García, Alejandro Rojo Sebastián, Andreina Olavarriá Delgadoc

aUnidad de Oncología Quirúrgica Digestiva, MD Anderson Cancer Center, Madrid, Spain
bUnidad de Oncología Médica Digestiva, MD Anderson Cancer Center, Madrid, Spain
cServicio de Anatomía Patológica, MD Anderson Cancer Center, Madrid, Spain
dServicio de Radiología, MD Anderson Cancer Center, Madrid, Spain
eCorresponding author.
E-mail address: oalonso@mdanderson.es (O. Alonso Casado).

2173-5077/$ – see front matter © 2012 AEC. Published by Elsevier España, S.L. All rights reserved.